MedPath

Retrotope, Inc.

Retrotope, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2006-01-01
Employees
1
Market Cap
-
Website
http://www.retrotope.com

Clinical Trials

14

Active:8
Completed:5

Trial Phases

3 Phases

Phase 1:8
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 1
8 (66.7%)
Phase 2
3 (25.0%)
Phase 3
1 (8.3%)

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Phase 2
Conditions
Progressive Supranuclear Palsy
Interventions
Drug: Placebo
First Posted Date
2021-06-24
Last Posted Date
2021-06-25
Lead Sponsor
Retrotope, Inc.
Target Recruit Count
40
Registration Number
NCT04937530
Locations
🇩🇪

Agaharied Teaching Hospital, University of Munich, Munich, MD, Germany

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Phase 3
Completed
Conditions
Friedreich's Ataxia
Interventions
Drug: Placebo
First Posted Date
2019-09-25
Last Posted Date
2022-05-27
Lead Sponsor
Retrotope, Inc.
Target Recruit Count
65
Registration Number
NCT04102501
Locations
🇺🇸

Collaborative Neuroscience Network, LLC, Long Beach, California, United States

🇺🇸

UCLA, Los Angeles, California, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

and more 3 locations

A Natural History Study of Infantile Neuroaxonal Dystrophy

Completed
Conditions
Neuroaxonal Dystrophy, Infantile
First Posted Date
2019-07-22
Last Posted Date
2022-04-08
Lead Sponsor
Retrotope, Inc.
Target Recruit Count
43
Registration Number
NCT04027816
Locations
🇨🇳

Peking University First Hospital, Beijing, China

🇪🇬

National Research Centre, Cairo, Egypt

🇮🇳

EN1 Neuro Services Pvt. Ltd, Mumbai, India

and more 2 locations

Natural History of Infantile Neuroaxonal Dystrophy

Completed
Conditions
INAD
Infantile Neuroaxonal Dystrophy
First Posted Date
2019-06-27
Last Posted Date
2020-06-29
Lead Sponsor
Retrotope, Inc.
Target Recruit Count
13
Registration Number
NCT03999814
Locations
🇺🇸

Sarah Endemann, Los Altos, California, United States

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Phase 2
Active, not recruiting
Conditions
Infantile Neuroaxonal Dystrophy
Interventions
First Posted Date
2018-06-27
Last Posted Date
2021-10-14
Lead Sponsor
Retrotope, Inc.
Target Recruit Count
19
Registration Number
NCT03570931
Locations
🇺🇸

University of California San Francisco, Benioff Children's Hospital, San Francisco, California, United States

🇺🇸

Jacobs Levy Genomics and Research Program, Morristown, New Jersey, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath